Neither Semax nor Selank is FDA-approved, and the blend has no established dosing framework. The figures below are commonly cited, anecdotal community amounts, not medically established. They are for education, not a personal protocol, and the safe default is to start low under professional supervision.
Overview
Semax and Selank were each formulated in their country of origin as intranasal solutions. A blend delivers both peptides in the same drops, so dosing is discussed per nasal administration and the two components' amounts are linked rather than independently adjustable.
Common dosing pattern
The pattern most often cited in community reports combines each component at its usual single-agent amount:
- Semax: roughly a few hundred micrograms per day intranasally.
- Selank: roughly a few hundred micrograms per day intranasally.
- Delivered together in the blend, often split across the day and used as a short course.
These are commonly cited, anecdotal, and not medically established. Because a blend fixes the ratio of the two peptides, you cannot adjust one without changing the other, which is why single-agent numbers do not transfer neatly.
Why start low
With two unapproved peptides in one product and no validated combination data, a conservative starting amount limits exposure while tolerability is assessed. Starting low and observing is the standard cautious approach when no authoritative label exists.
How it is administered
The studied route for both components is intranasal, relying on absorption across the nasal mucosa. Their short half-lives are one reason daily or divided dosing is described rather than weekly.
- Concentration reflects how much of each peptide is present per volume of finished solution.
- Injectable forms sold elsewhere are not interchangeable with the intranasal solution, so a figure from one route does not apply to the other.
- With unregulated research chemicals, identity and purity vary, so even careful math rests on assumptions.
Why oversight matters
Both peptides act on the nervous system, and combination effects and interactions are not characterized. Because neither is approved, there is no verified product and no clinician-set dose. Any concrete decision belongs with a qualified clinician; the commonly cited ranges above are context, not a protocol.